#USA #Los Gatos #Shifamed #Akura Medical #VTE Care

Akura Medical Raises $53 Million in Series C Funding to Advance VTE Care Innovations

Akura Medical Secures $53 Million in Series C Financing

Akura Medical, a portfolio company of Shifamed, has successfully completed a Series C funding round amounting to $53 million. This substantial investment aims to further develop their Katana™ Thrombectomy System and the NavIQ™ quantification software, while also completing recruitment for the QUADRA-PE Study and achieving critical regulatory milestones.

Strategic Financing

The financing round was led by the Qatar Investment Authority (QIA), with participation from existing investors. A portion of these funds will be allocated towards establishing a joint venture in Qatar. Amr Salahieh, Chairman and current CEO of Akura Medical, stated, "Akura Medical is creating a differentiated portfolio of technologies aimed at enhancing the precision of thrombectomy procedures and improving patient outcomes. The recent introduction of our NavIQ quantification software reflects our commitment to advancing intelligent, data-driven thrombectomy practices. This new capital will help accelerate product development and lay the groundwork for sustainable growth. We appreciate QIA's trust and partnership as we work to realize our vision."

Innovative Product Portfolio

The heart of Akura Medical’s product line is the Katana Thrombectomy System, designed to effectively remove various types of blood clots. This intelligent system aims to optimize catheter delivery and offers additional intraoperative feedback. Notably, it employs high-speed saline jet technology to effectively dissolve clots irrespective of their morphology while preventing catheter occlusions, ensuring a more efficient procedure. Furthermore, the system is equipped with sensors providing real-time data on pulmonary artery pressure, which facilitates insights into the intervention's progress.

On the other hand, NavIQ is a groundbreaking quantification software that transforms CT angiograms into a 3D model of the pulmonary vascular system. This model aids in the anatomical visualization of arteries and clots, streamlining pre-procedure planning. In addition, NavIQ is engineered to deliver data that characterizes blood clots, enabling physicians to prioritize treatment effectively.

The Urgent Need for Innovation

Venous thromboembolism (VTE) is a major public health issue, ranking as the third leading cause of cardiovascular deaths in the United States. Typically arising from blood clots formed in deep veins of the legs, VTE can severely impede or completely block blood flow to the lungs, implying a critical need for innovative treatment solutions.

About Akura Medical

Akura Medical is a privately held medical device company that specializes in treating VTE. With its flagship Katana Thrombectomy System, the company strives to redefine treatment standards for pulmonary embolisms by enabling more efficient removal of various clot types. Akura Medical embodies the mission to reshape the landscape of VTE treatment and sustainably improve the lives of patients globally. To learn more about Akura Medical, visit www.akuramedical.com.

Note: The Katana System is intended for research purposes only and is not approved for sale in the USA or in all countries.

About Shifamed

Founded by serial entrepreneur Amr Salahieh, Shifamed is a specialized center for medical innovation focused on developing solutions that accelerate market entry, reduce risk, enhance impact, and pave the way for a world where patients can enjoy longer, healthier lives. For more information about Shifamed, please visit www.shifamed.com.